Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 443216

Next Previous
X
Search
Drug Profile

SAR 443216

Alternative Names: HER2/CD28xCD3 trispecific binding protein - Sanofi; SAR-443216; Trispecific antibody (CD3xCD28xHER2) - Sanofi

Latest Information Update: 01 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Antineoplastics; Immunotherapies; Trispecific antibodies
  • Mechanism of Action CD28 antigen stimulants; CD3 antigen stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Gastric cancer

Most Recent Events

  • 13 Sep 2024 Efficacy, adverse events and pharmacokinetics data from the phase I trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 23 Feb 2024 Discontinued - Phase-I for Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Spain, South Korea, Belgium, China, Taiwan, France (IV) prior to February 2024
  • 01 Feb 2024 Sanofi terminates a phase I trial in Gastric cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in France, Taiwan, China, Belgium, South Korea, Spain, USA (IV) based on preliminary results

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top